Skip to content

Study · Animal study (in vivo) · rat · 2024

4 results

Ameliorative Effects of Larazotide Acetate on Intestinal Permeability and Bacterial Translocation in Acute Pancreatitis Model in Rats.

Karahan D, Harputluoglu MMM, Gul M, Gunduz A, Ozyalin F, İnceoğlu F, Tikici D, Yılmaz İ, Satilmis B

Digestive diseases and sciences5 Mar 2024Cited by 2 (Europe PMC)

PMID38441784 (opens in a new tab)DOI10.1007/s10620-024-08326-8 (opens in a new tab)PepBankPUB-38441784
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute pancreatitis, prophylactic larazotide reduced intestinal damage scores versus the AP group.

    In plain wordsIn rats with acute pancreatitis, larazotide reduced intestinal damage scores compared with the AP group.

    Peptide
    Larazotide
    Outcome
    DecreaseIntestinal damage score
    Study

    ratn: not reported in source

    L-arginine-induced acute pancreatitis in male Sprague-Dawley rats
    Comparator
    AP group
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.01 mg/mL · oral · 7 days before L-arginineAs given in this study (rat).

    Source sentences

    Summary
    Intestinal damage scores, anti-Zo-1 immunoreactivity H-score, serum FITC-Dextran levels, and bacterial translocation frequency (50% versus 100%) were significantly lower in the AP + LAR group compared to the AP group (all p < 0.01).
    2 context sentences
    Summary · context
    Thirty-two male Sprague-Dawley rats were divided into 4 groups; control, larazotide (LAR), AP, and AP + LAR.
    Summary · context
    AP + LAR group received prophylactic 0.01 mg/mL LA orally for 7 days before the first dose of L-Arginine.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats with acute pancreatitis, larazotide reduced anti-Zo-1 immunoreactivity H-score versus the AP group.

    In plain wordsIn rats with acute pancreatitis, larazotide reduced anti-Zo-1 staining scores compared with the AP group.

    Peptide
    Larazotide
    Outcome
    DecreaseAnti-Zo-1 immunoreactivity H-score
    Study

    ratn: not reported in source

    L-arginine-induced acute pancreatitis in male Sprague-Dawley rats
    Comparator
    AP group
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.01 mg/mL · oral · 7 days before L-arginineAs given in this study (rat).

    Source sentences

    Summary
    Intestinal damage scores, anti-Zo-1 immunoreactivity H-score, serum FITC-Dextran levels, and bacterial translocation frequency (50% versus 100%) were significantly lower in the AP + LAR group compared to the AP group (all p < 0.01).
    2 context sentences
    Summary · context
    Thirty-two male Sprague-Dawley rats were divided into 4 groups; control, larazotide (LAR), AP, and AP + LAR.
    Summary · context
    AP + LAR group received prophylactic 0.01 mg/mL LA orally for 7 days before the first dose of L-Arginine.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute pancreatitis, larazotide reduced serum FITC-Dextran levels versus the AP group.

    In plain wordsIn rats with acute pancreatitis, larazotide reduced serum FITC-Dextran compared with the AP group.

    Peptide
    Larazotide
    Outcome
    DecreaseSerum FITC-Dextran
    Study

    ratn: not reported in source

    L-arginine-induced acute pancreatitis in male Sprague-Dawley rats
    Comparator
    AP group
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.01 mg/mL · oral · 7 days before L-arginineAs given in this study (rat).

    Source sentences

    Summary
    Intestinal damage scores, anti-Zo-1 immunoreactivity H-score, serum FITC-Dextran levels, and bacterial translocation frequency (50% versus 100%) were significantly lower in the AP + LAR group compared to the AP group (all p < 0.01).
    2 context sentences
    Summary · context
    Thirty-two male Sprague-Dawley rats were divided into 4 groups; control, larazotide (LAR), AP, and AP + LAR.
    Summary · context
    AP + LAR group received prophylactic 0.01 mg/mL LA orally for 7 days before the first dose of L-Arginine.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute pancreatitis, bacterial translocation occurred in 50% with larazotide versus 100% in the AP group.

    In plain wordsIn rats with acute pancreatitis, larazotide reduced bacterial translocation compared with the AP group.

    Peptide
    Larazotide
    Outcome
    DecreaseBacterial translocation
    Study

    ratn: not reported in source

    L-arginine-induced acute pancreatitis in male Sprague-Dawley rats
    Comparator
    AP group
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.01 mg/mL · oral · 7 days before L-arginineAs given in this study (rat).

    Measurements

    Bacterial translocation
    50%
    AP + LAR
    Bacterial translocation
    100%
    AP

    Source sentences

    Summary
    Intestinal damage scores, anti-Zo-1 immunoreactivity H-score, serum FITC-Dextran levels, and bacterial translocation frequency (50% versus 100%) were significantly lower in the AP + LAR group compared to the AP group (all p < 0.01).
    2 context sentences
    Summary · context
    Thirty-two male Sprague-Dawley rats were divided into 4 groups; control, larazotide (LAR), AP, and AP + LAR.
    Summary · context
    AP + LAR group received prophylactic 0.01 mg/mL LA orally for 7 days before the first dose of L-Arginine.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.